ABC | Volume 110, Nº2, February 2018

Original Article Leiria et al Uninterrupted anticoagulants and flutter ablation Arq Bras Cardiol. 2018; 110(2):151-156 5. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. 6. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, et al; X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346-55. doi: 10.1093/ eurheartj/ehu367. 7. Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, et al; ENSURE-AF investigators. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016;388(10055):1995-2003. doi: 10.1016/S0140-6736(16)31474-X. 8. Finlay M, Sawhney V, Schilling R, Thomas G, Duncan E, Hunter R, et al. Uninterrupted warfarin for periprocedural anticoagulation in catheter ablation of typical atrial flutter: A safe and cost-effective strategy. J Cardiovasc Electrophysiol. 2010;21(2):150-4. doi: 10.1111/j.1540-8167.2009.01603.x. 9. Wu S, Yang YM, Zhu J, Wan HB, Wang J, Zhang H, et al. Meta-analysis of efficacy and safety of neworal anticoagulants comparedwith uninterrupted vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation. Am J Cardiol. 2016;117(6):926-34. doi: 10.1016/j. amjcard.2015.12.027. 10. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263-72. doi: 10.1378/chest.09-1584. 11. Grönefeld GC, Wegener F, Israel CW, Teupe C, Hohnloser SH. Thromboembolicriskofpatientsreferredforradiofrequencycatheterablation of typical atrial flutter without prior appropriate anticoagulation therapy. Pacing Clin Electrophysiol. 2003;26(1 Pt 2):323-7. PMID: 12687838. 12. Kaiser DW, Streur MM, Nagarakanti R, Whalen SP, Ellis CR. Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. J Interv Card Electrophysiol. 2013;37(3):241-7. doi: 10.1007/ s10840-013-9793-7. 13. Kaess BM, Ammar S, Reents T, Dillier R, Lennerz C, Semmler V, et al. Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon. Am J Cardiol. 2015;115(1):47-51. doi: 10.1016/j. amjcard.2014.10.005. 14. Kiehl EL, Makki T, Kumar R, Gumber D, KwonDH, Rickard JW, et al. Incidence andpredictorsofrightventricularpacing-inducedcardiomyopathyinpatientswith complete atrioventricular block and preserved left ventricular systolic function. HeartRhythm.2016;13(12):2272-8.doi:10.1016/j.hrthm.2016.09.027. 15. Amara W, Fromentin S, Dompnier A, Nguyen C, Allouche E, Taieb J, et al. Neworal anticoagulants in patients undergoing atrial flutter radiofrequency catheter ablation: an observational study. Future Cardiol. 2014;10(6):699- 705. doi: 10.2217/fca.14.70. 16. Glover BM, Chen J, Hong KL, Boveda S, Baranchuk A, Haugaa KH, et al. Catheter ablation for atrial flutter: a survey by the European Heart Rhythm Association andCanadianHeart RhythmSociety. Europace. 2017;19(4):e1. doi: 10.1093/europace/euw392. 17. Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand JP, Berge E, et al; GARFIELD-AF Investigators. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103(4):307- 314. doi: 10.1136/heartjnl-2016-309832. 18. Klimek-PiotrowskaW, HoldaMK, Koziej M, Holda J, Piatek K, Tyrak K, et al. Clinical anatomy of the cavotricuspid isthmus and terminal crest. PLoSOne. 2016;11(9):e0163383. doi: 10.1371/journal.pone.0163383. 19. AsirvathamSJ.Correlativeanatomyandelectrophysiologyfortheinterventional electrophysiologist: right atrial flutter. J Cardiovasc Electrophysiol. 2009;20(1):113-22. doi: 10.1111/j.1540-8167.2008.01344.x. 20. Melo SL, Scanavacca MI, Darrieux FC, Hachul DT, Sosa EA. Ablation of typical atrial flutter : a prospective randomized study of cooled-tip versus 8-mm-tip catheters. Arq Bras Cardiol. 2007;88(3):273-8. doi: http://dx.doi . org/10.1590/S0066-782X2007000300004. 21. Leiria TL, Becker G, Kus T, Essebag V, Hadjis T, Sturmer ML. Improved flutter ablation outcomes using a 10mm-tip ablation catheter. Indian Pacing Electrophysiol J. 2010;10(11):496-502. PMID: 21197277. 22. Feld G, Wharton M, Plumb V, Daoud E, Friehling T, Epstein L; EPT-1000 XP Cardiac Ablation System Investigators. Radiofrequency catheter ablation of type 1 atrial flutter using large-tip 8- or 10-mm electrode catheters and a high-output radiofrequency energy generator: results of amulticenter safety and efficacy study. J AmColl Cardiol. 2004;43(8):1466-72. doi: 10.1016/j. jacc.2003.11.036. 23. Leiria TL, Pellanda L, MiglioranzaMH, Sant’anna RT, Becker LS, Magalhães E, et al. Warfarin and phenprocoumon : experience of an outpatient anticoagulation clinics. Arq Bras Cardiol. 2010;94(1):41-5. http://dx.doi . org/10.1590/S0066-782X2010000100008. This is an open-access article distributed under the terms of the Creative Commons Attribution License 156